Therapeutic Strategies in Myeloma

CE / CME

Therapeutic Strategies in Multiple Myeloma: Overview of Current and Emerging Treatment Options

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Nurses: 1.00 Nursing contact hour

Released: April 26, 2023

Expiration: April 25, 2024

Shaji K. Kumar
Shaji K. Kumar, MD

Activity

Progress
1
Course Completed

Statistics

Shaji K. Kumar, MD
The incidence of MM differs significantly by race. In the US, MM is twice as common in Black vs White patients. Epidemiologic studies show that MM develops about a decade earlier in Black patients compared with White patients. Studies are ongoing to better understand differences in the disease biology among different groups of patients.1-3

Access to Care

Retrospective studies have shown that Black patients with MM are less likely to receive therapies such as multidrug combinations and ASCT compared to White patients. This may contribute to inferior survival outcomes.3-5

Similar or Improved Survival With Equal Access to Care

Based on the studies from the CoMMpass and Connect MM US registries, Black patients who have access to the same type of care as White patients have comparable outcomes. Thus, the differences in survival may not be due to biology, but access to equal care.4,6 Disparities in care for our patients with MM are a major issue, and it is important to be aware of these health disparities as well as continue to advocate for our patients to ensure access to the optimal treatment for their disease.